The US pharmaceutical drug delivery market is projected to rise from USD 0.94 billion in 2026 to USD 1.24 billion by 2031 at a 5.8% CAGR. Injectables, oncology applications, and home care settings are expected to post the fastest growth.
Europe's infusion pump market is projected to reach USD 7.09 billion by 2031 at a 6.8% CAGR. Growth is driven by connected systems, tighter safety standards, homecare use, and diabetes demand.
The healthcare 3D printing market is projected to reach $14.6 billion by 2033, while the bioinks market is anticipated to reach USD 683.6 million. Growth is tied to personalised medical solutions, tissue engineering, drug discovery, and advances in biomaterials.
CRISPR Therapeutics reported a $581.6 million net loss in 2025 with revenue of just $3.5 million, while continuing to advance its gene-editing pipeline including the approved CASGEVY therapy and next-generation CAR T cell programs. The company maintains strategic partnerships and expects current funds to support operations for at least 24 months.
Analysis of 585 clinical trials reveals region is the primary driver of risk variation, with North America showing 29% higher screen failure rates. Heart failure trials show severe underrepresentation, with only 14.5% of participants from outside Europe and North America despite Asia having 50% of global heart failure cases. Central monitoring methods and representativeness indices are proposed to address these disparities.
Origin Genomics launches to pursue germline gene editing research despite US prohibitions, while Thermo Fisher completes its $8.88 billion acquisition of Clario Holdings. Lucid Diagnostics reports Q4 revenue growth, and multiple partnerships form across the diagnostics and synthetic biology sectors.
Three recent studies reveal connections between gut microbiome composition and health outcomes, identifying specific bacterial groups associated with recovery and disease, plus genetic variants that shape microbial communities.
YolTech Therapeutics received FDA approval for its IND application for YOLT-202, an in vivo gene-editing therapy for Alpha-1 Antitrypsin Deficiency. Interim data from an ongoing trial showed rapid increases in AAT levels to normal range with favorable safety.
New market reports forecast significant expansion in CAR T-cell therapy, US pharmaceutical drug delivery, and healthcare nanotechnology sectors, driven by chronic disease prevalence and technological advances.
The global precision medicine market reached $82.1 billion in 2025 and is expected to grow to $179.4 billion by 2034. Researchers emphasize that precision nutrition interventions must demonstrate cost-effectiveness to deliver patient benefits.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07599540 |
Cardiovascular Risk in Peripheral Artery Disease Patients Undergoing Endovascular Revascularisation |
ACTIVE_NOT_RECRUITING | |
| NCT07595718 |
AI-Based Phenome Data Analysis for Predicting the Onset of Major Diseases |
RECRUITING | |
| NCT07563777 |
100-Year Human Aging Study |
RECRUITING | |
| NCT07557108 |
Fascial Plane Blocks and Quality of Recovery in Cardiac Surgery |
RECRUITING | |
| NCT07550036 |
WomenFocused Education in CArdiac REhabilitation (WECARE) Pilot RCT |
NOT_YET_RECRUITING | NA |
| NCT07543731 |
A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab |
NOT_YET_RECRUITING | |
| NCT07542860 |
Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients |
RECRUITING | |
| NCT07539987 |
Evaluation of a Novel Indoor Air Pollution Intervention Among Older Adults |
NOT_YET_RECRUITING | NA |
| NCT07539532 |
Comparing Traditional Risk Scores and an AI-Based Multimodal Model for Predicting Cardiovascular Events After Gastrointestinal Surgery |
RECRUITING | |
| NCT07524101 |
Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD |
NOT_YET_RECRUITING | NA |
